Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain

Neurochemical Research

Volumn 29, Issue 10, 2004, Pages 1897-1911

  Chauhan, Neelima B ^a   Siegel, George J ^b   Feinstein, Douglas L ^a  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

A ; Alzheimer's disease; apoptosis; IL 1 ; myopathy; statin

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; CYTOKINE; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; MEVINOLIN; PEPTIDE; PRAVASTATIN; SUCCINATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; HISTOCHEMISTRY; HYDROPHILICITY; INFLAMMATION; LIPOPHILICITY; LIVER TOXICITY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; BRAIN CHEMISTRY; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOVASTATIN; MALE; MICE; MICE, INBRED C3H; MICE, TRANSGENIC; PRAVASTATIN; PROTEIN PROCESSING, POST-TRANSLATIONAL;

ANIMALIA;

EID: 4644308807     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NERE.0000042217.90204.8d     Document Type: Article

References (72)

1. Alberts, A. W. 1988. Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 62(15):10J-15J.
2. Williams, D. and Feely, J. 2002. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41(5):343-370.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25):3143-3421.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. 2002. Lancet 360(9326):7-22.
5. Summary for patients in: Curr Cardiol Rep. 2002 Nov; 4(6):486-487.
6. Chauhan, N. B. 2003. Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease. J. Lipid Res. 44(11):2019-2029.
7. Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., Duff, K., and Pappolla, M. A. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7(4):321-331.
8. Erratum in: Neurobiol. Dis. 7(6 Pt B):690.
9. Poirier, J. 2000. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. N. Y. Acad. Sci. 924:81-90.
10. Holtzman, D. M., Fagan, A., and M., Mackey, B., Tenkova, T., Sartorius, L., Paul, S. M., Bales, K., Ashe, K. H., Irizarry, M. C., and Hyman, B. T. 2000. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47(6):739-747.
11. Sawamura, N., Gong, J. S., Garver, W. S., Heidenreich, R. A., Ninomiya, H., Ohno K., Yanagisawa, K., and Michikawa, M. 2001. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J. Biol. Chem. 276(13):10314-10319.
12. Runz, H., Rietdorf, J., Tomic, I., de Bernard, M., Beyreuther, K., Pepperkok, R., and Hartmann, T. 2002. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22(5):1679-1689.
13. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57(10):1439-1443.
14. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. 2000. Statins and the risk of dementia. Lancet 356(9242):1627-1631.
15. Erratum in: Lancet 357(9255):562.
16. Hajjar, I., Schumpert, J., Hirth, V., Wieland, D., and Eleazer, G. P. 2002. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J. Gerontol. A. Biol. Sci. Med. Sci. 57(7):M414-M418.
17. Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., and McDowell, I. 2002. Use of lipid-lowering agents indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59(2):223-227.
18. Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B, Schmidt, S. D., Thomas-Bryant, T., Tint, G. S, Wang, R., Mercken, M., Petanceska, S. S., and Duff, K. E. 2001. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8(5):890-899.
19. Petanceska, S. S., DeRosa, S., Olm, V., Diaz, N., Sharma, A., Thomas-Bryant, T., Duff, K., Pappolla, M., and Refolo, L. M. 2002. Statin therapy for Alzheimer's disease: will it work? J. Mol. Neurosci. 19(1-2):155-161.
20. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Kuhl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K., and Hartmann, T. 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo Proc. Natl. Acad. Sci. U.S.A. 98(10):5856-5861.
21. Liao, J. K. 2002. Beyond lipid lowering: The role of statins in vascular protection. Int. J. Cardiol. 86(1):5-18.
22. Vaughan, C. J. 2003. Prevention of stroke and dementia with statins: Effects beyond lipid lowering. Am. J. Cardiol. 91(4A):23B-29B.
23. Cucchiara, B., and Kasner, S. E. 2001. Use of statins in CNS disorders. J. Neurol. Sci. 187(1-2):81-89.
24. Stuve, O., Youssef, S., Steinman, L., and Zamvil, S. S. 2003. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol. 16(3):393-401.
25. Tringali, G., Vairano, M., Dello, Russo, C., Preziosi, P., and Navarra, P. 2004. Lovastatin and mevastatin reduce basal and cytokine-stimulated production of prostaglandins from rat microglial cells in vitro: evidence for a mechanism unrelated to the inhibition of hydroxy-methyl-glutaryl CoA reductase. Neurosci. Lett. 354(2):107-110.
26. Fukami, M., Maeda, N., Fukushige, J., Kogure, Y., Shimada, Y., Ogawa, T., and Tsujita, Y. 1993. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res. Exp. Med. (Berl). 193(5):263-273.
27. Reijneveld, J. C., Koot, R. W., Bredman, J. J., Joles, J. A., Bar, P. R. 1996. Differential effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr. Res. 39(6):1028-1035.
28. Nakahara, K., Kuriyama, M., Sonoda, Y., Yoshidome, H., Nakagawa, H., Fujiyama, J., Higuchi, I., and Osame, M. 1998. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol. 152(1):99-106.
29. Gerson, R. J., MacDonald, J. S., Alberts, A. W., Kornbrust, D. J., Majka, J. A., Stubbs, R. J., and Bokelman, D. L. 1989. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am. J. Med. 87(4A):28S-38S.
30. MacDonald, J. S., Gerson, R. J., Kornbrust, D. J., Kloss, M. W., Prahalada, S., Berry, P. H., Alberts, A. W., and Bokelman, D. L. 1988. Preclinical evaluation of lovastatin. Am. J. Cardiol. 62(15):16J-27J.
31. Davidson, M. H. 2001. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 61(2):197-206.
32. Chishti, M. A., Yang, D. S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., Turner, S., Lozza, G., Grilli, M., Kunicki, S., Morissette, C., Paquette, J., Gervais, F., Bergeron, C., Fraser, P. E., Carlson, G. A., George-Hyslop, P. S., and Westaway, D. 2001. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276(24):21562-21570.
33. Tobert, J. A. 1988. Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 62(15):28J-34J.
34. Chauhan, N. B. and Siegel, G. J. 2002. Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. J. Neurosci. Res. 69(1):10-23.
35. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
36. Chauhan, N. B. and Siegel, G. J. 2003. Effect of PPF and ALCAR on the induction of NGF-and p75-mRNA and on APR processing in Tg2576 brain. Neurochem. Int. 43(3):225-233.
37. Chauhan, N. B., Lichtor, T., and Siegel, G. J. 2003. Aging potentiates Abeta-induced depletion of SNAP-25 in mouse hippocampus. Brain Res. 982(2):219-227.
38. Chauhan, N. B. and Siegel, G. J. 2003. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J. Neurosci. Res. 74(1):142-147.
39. Simons, M., Keller, P., Dichgans, J. and Schulz, J. B. 2001. Cholesterol and Alzheimer's disease: is there a link? Neurology 57(6):1089-1093.
40. Selkoe, D. J. and Lansbury, P. J., Jr. 1999. Biochemistry of Alzheimer's and Prion Diseases. pp. 949-968. in Siegei, G. J., Agranoff B. W., Albers, R. W., Fisher, S. K. and Uhler, M. D. (eds.), Basic Neurochemistry. Lippincot Raven, New York.
41. Mori, C., Spooner, E., and T., Wisniewski, K. E., Wisniewski, T. M., Yamaguch, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., and Lemere, C. A. 2002. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9(2):88-102.
42. Sparks, D. L., Martin, T. A., Gross, D. R., Hunsaker, J. C. 2000. 3rd Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc. Res. Tech. 50(4):287-90.
43. Fukami, S., Watanabe, K., Iwata, N., Haraoka, J., Lu, B., Gerard, N. P., Gerard, C., Fraser, P., Westaway, D., St George-Hyslop, P., and Saido, T. C. 2002. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci. Res. 43(1):39-56.
44. Yasojima, K., McGeer, E. G., McGeer, P. L. 2001. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919(1):115-121.
45. Mohajeri, M. H., Wollmer, M. A., and Nitsch, R. M. 2002. Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J. Biol. Chem. 277(38):35460-35465.
46. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., and Simons, K. 1998. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 95(11):6460-6464.
47. Frears, E. R., Stephens, D. J., Walters, C. E., Davies, H., and Austen, B. M. 1999. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10(8):1699-1705.
48. Karten, B., Vance, D. E., Campenot, R. B., and Vance, J. E, 2003. Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons. J. Biol. Chem. 278(6):4168-4175.
49. Tanaka, T., Tatsuno, I., Noguchi, Y., Uchida, D., Oeda, T., Narumiya, S., Yasuda, T., Higashi, H., Kitagawa, M., Nakayama, K., Saito, Y., and Hirai, A. 1998. Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes. Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression. J. Biol. Chem. 273(41):26772-26778.
50. Danesh, F. R., Sadeghi, M. M., Amro, N., Philips, C., Zeng, L., Lin, S., Sahai, A., and Kanwar, Y. S. 2002. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc. Natl. Acad. Sci U.S.A. 99(12):8301-8305.
51. Molnar, G., Dagher, M. C., Geiszt, M., Settleman, J., and Ligeti, E. 2001. Role of prenylation in the interaction of Rho-family small GTPases with GTPase activating proteins. Biochemistry 40(35):10542-10549.
52. de Toledo, M., Senic-Matuglia, F., Salamero, J., Uze, G., Comunale, F., Fort, P., and Blangy, A. 2003. The GTP/GDP cycling of rho GTPase TCL is an essential regulator of the early endocytic pathway. Mol. Biol. Cell. 14(12):4846-4856.
53. Koo, E. H., and Squazzo, S. L. 1994. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269(26):17386-17389.
54. Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y., and Haass, C. 1997, Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J. Biol. Chem. 272(26):16085-16088.
55. Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., and Nixon, R. A. 2000. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157(1):277-286.
56. Kojro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Nail. Acad. Sci. U.S.A. 98(10):5815-5820.
57. Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. 2003. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160(1):113-123.
58. Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A., Berezovska, O., Hyman, B. T., Chang T. Y., Tanzi, R. E., and Kovacs, D. M. 2001. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3(10):905-912.
59. Davies, J. P., Chen, F. W., and Ioannou, Y. A. 2000. Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 290(5500):2295-2298.
60. Yamazaki, T., Chang, T. Y., Haass, C., and Ihara, Y. 2001. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells. J. Biol. Chem. 276(6):4454-4460.
61. Fukumoto, H., Deng, A., Irizarry, M. C., Fitzgerald, M. L., and Rebeck, G. W. 2002. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J. Biol. Chem. 277(50):48508-48513.
62. Garcia-Roman, N., Alvarez, A. M., Toro, M. J., Montes, A., and Lorenzo, M. J. 2001. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol. Cell Neurosci. 17(2):329-341.
63. Monje, M. L., Toda, H., and Palmer, T. D. 2003. Inflammatory blockade restores adult hippocampal neurogenesis Science 302(5651):1760-1765.
64. Konsman, J. P., Parnet, P., and Dantzer, R. 2002. Cytokine-induced sickness behaviour: mechanisms and implications. Trends. Neurosci. 25(3):154-159.
65. Capuron. L. and Dantzer. R. 2003. Cytokines and depression: The need for a new paradigm. Brain Behav. Immun. 17 (Suppl 1).S119-124.
66. Noe, B., Hagenbuch, B., Stieger, B., and Meier, P. J. 1997. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. U.S.A. 94(19):10346-10350.
67. Gao, B., Stieger, B., Noe, B., Fritschy, J. M., and Meier, P. J. 1999. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J. Histochem. Cytochem. 47(10):1255-1264.
68. de Chaves, E. I., Rusinol, A. E., Vance, D. E., Campenot, R. B., and Vance, J. E. 1997. Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. J. Biol. Chem. 272(49):30766-30773.
69. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W. P., and Kirchgessner, T. G. 1999. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274(52):37161-37168.
70. van Vliet, A. K., van Thiel, G. C., Huisman, R. H., Moshage, H., Yap, S. H., and Cohen, L. H. 1995. Different effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim. Biophys. Acta. 1254(1):105-111.
71. Cohen, L. H., van Leeuwen, R. E., van Thiel, G. C., van Pelt, J. F., and Yap, S. H. 2000. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm. Drug. Dispos. 21(9):353-364.
72. Rosenson, R. S. 2004. Current view of statin-induced myopathy. Am. J. Med. 116(6):775-777.